Androgen News and Research

RSS

Passing on Polycystic Ovary Syndrome: Health risks for Male offspring of Women with PCOS

In this interview, we spoke to two researchers from the Karolinska Institutet about their latest work that investigated how PCOS can affect the health of future generations of men.

29 May 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

26 May 2023

Humanized mouse model for rare genetic disease developed for the first time

Mice with a defected human gene responsible for a rare genetic disease, called congenital adrenal hyperplasia, have been developed for the first time.

15 May 2023

Experts urge increased attention to the threat of climate change and pollution on children's health

Study explores the impact of climate change and environmental chemicals on children's health.

9 May 2023

Obesity management: a women's health approach

Researchers provide a women's health perspective on obesity.

1 May 2023

Mouse studies can help find better therapeutic targets for people with PCOS

Polycystic ovarian syndrome, or PCOS, can cause a range of symptoms, including disrupted menstrual cycles, abdominal obesity, cardiovascular disease, and type 2 diabetes.

18 Apr 2023

Clinical trial of ENZAMET shows promising results for men with advanced prostate cancer

A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.

28 Mar 2023

Discovery enables a clear diagnosis for more patients with androgen insensitivity syndrome

Steroid hormones, to which belong sex hormones like estrogen or testosterone, are important signaling molecules and are responsible among other things for controlling female and male phenotypic sex differentiation.

27 Mar 2023

Drug combination may reduce the risk of prostate cancer progression, death

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

17 Mar 2023

How the structural and functional effects of mutations on androgen receptor lead to prostate cancer

The androgen receptor is a key transcriptional factor for the proper sex development —specially in males— and the physiological balance of all the tissues that express this receptor.

17 Mar 2023

Cedars-Sinai study reveals new insights into the effects of hormonal treatment for transgender men

New insights into the effects of a hormonal treatment for transgender men, discovered by Cedars-Sinai investigators, could have implications for the treatment of breast cancer.

8 Mar 2023

Multi-organ scRNA-seq reveals targeting pro- or anti-inflammatory regulators may be exploited for personalized treatment of immune diseases

Researchers performed multi-organ single-cell RNA sequencing of collagen-induced arthritis murine model to evaluate immune-mediated inflammatory disease alterations by characterizing the genome, organizing the organome, and prioritizing pathways in the multi-organ data.

3 Mar 2023

Study highlights the interconnectedness of autoimmunity and cancer

In a recent study published in the journal Immunity, researchers reviewed the T cell response in cancer and autoimmunity to propose strategies for more effective immunotherapies.

15 Feb 2023

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology, an Official Journal of the American Urological Association.

10 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

Targeting a single enzyme can kill prostate cancer cells

For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα.

3 Feb 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

Keto diet as a PCOS treatment

A recent study explores the role of the ketogenic diet in the treatment of polycystic ovarian syndrome.

29 Jan 2023

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

Expansion of intermediate cells in prostate cancer correlates with treatment resistance and poor outcomes

Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour no longer responds to hormone deprivation therapy.

14 Dec 2022